Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study
复制标题
DOI：
10.1086/504874
复制
发表时间：
2006-07-01
影响因子：
11.8
通讯作者：
Mallal, Simon
中科院分区：
文献类型：
--
作者：
Rauch, A.;Nolan, D.;Mallal, Simon
阿巴卡韦治疗与8%的接受者的显著药物超敏反应相关，回顾性研究表明与HLA-B*5701等位基因有很强的遗传相关性。在这项前瞻性研究中，涉及260个阿巴卡韦初治个体（其中7.7%为HLA-B*5701阳性），我们证实了遗传风险分层的有用性，在148个HLA-B*5701阴性接受者中没有阿巴卡韦过敏病例。
Abacavir therapy is associated with significant drug hypersensitivity in similar to 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle. In this prospective study, involving 260 abacavir-naive individuals ( 7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701 negative recipients.